Evid Science leverages cutting edge AI and ML to build the largest database of scientific evidence in the world. Their platform tracks and finds actionable data by ingesting the entire primary literature of peer-reviewed articles and letting users access customized, evidence-based content for data-driven decision making and clinical support, enabling medical researchers to optimize and simplify clinical study and generate comparative cost analyses in real time.
Evid Science was acquired by Genesis Research in January, 2021.
Evid Science was acquired by Genesis Research in January, 2021.
Location: United States, California, El Segundo
Employees: 1-10
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | SPRIM Vent... | sprim.com |
| - | Wavemaker ... | wavemaker3... |
| - | SPRIM Glob... | sprim.net |
Mentions in press and media 4
| Date | Title | Description |
| 03.02.2025 | NAWSI’s Genesis AI Pro 5.0 Secures $50 Million Institutional Order | Buffalo, NY, Feb. 03, 2025 (GLOBE NEWSWIRE) -- In the rapidly evolving landscape of financial markets, North American Wealth Strategy Institute (NAWSI) has announced that its cutting-edge AI trading system, Genesis AI Pro 5.0, has secured a... |
| 07.01.2021 | Genesis Research Announces Acquisition of Evid Science | Combined, we are the next generation of technology enabled life science services. HOBOKEN, N.J. (PRWEB) January 07, 2021 Genesis Research LLC (GR), a Value Demonstration Company providing Real World Evidence (RWE) and Health Economics and O... |
| 07.01.2021 | Genesis Research Announces Acquisition of Evid Science | HOBOKEN, N.J. (PRWEB) JANUARY 07, 2021 Genesis Research LLC (GR), a Value Demonstration Company providing Real World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services to the health and life sciences industries, anno... |
| 15.11.2018 | Evid Science Receives Seed Capital to Advance Clinical AI Platform | LOS ANGELES, CA (February 15, 2018) – Evid Science, an artificial intelligence (AI) company for the pharmaceutical industry, has successfully secured seed funding from TKS I, a new private equity fund dedicated to early-stage life science c... |